DP303c in Patients With HER2-positive Advanced Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Advanced Breast Cancer
Interventions: DRUG: DP303c|DRUG: Trastuzumab|DRUG: Vinorelbine Tartrate|DRUG: Capecitabine tablets
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.